Fleury S.A. reported its third-quarter 2026 (Q3 2026) financial results, posting a net income of R$ 264.3 million, a 42.9% increase compared to Q3 2025. The results accelerate the group's profitability, with ROIC climbing to 18.7%, though they also leave investors weighing the screen price against an estimated fair value of R$ 19.02.
How Do FLRY3 Metrics Look After the Q3 2026 Earnings Release?
Fleury's Q3 2026 earnings release, detailed in the company's financial statements, showed operational acceleration across key indicators tracked on analysis platforms like Fundamentus. Consolidated gross revenue reached R$ 2,695.5 million for the quarter, marking a 13.3% year-over-year jump—with 9.9% coming from organic expansion and 9.3% driven specifically by the B2C segment.
On the operational front, EBITDA totaled R$ 672.2 million between July and September 2026, up 12.2% year-over-year, keeping the EBITDA margin at a strong 27.1%. More than top-line revenue, the primary driver for the bottom line was efficiency gains and a drop in the effective income tax rate, which fell from 22.8% in Q3 2025 to 17.3% in Q3 2026.
Return on invested capital (ROIC) reached 18.7%, sitting 470 basis points above the levels observed during the merger process with Hermes Pardini. This confirms that the integration of the diagnostic networks and disciplined capital allocation have begun generating real returns for the group's combined structure.
What Explains Fleury's Jump in Net Income and Margin?
The 42.9% expansion in net income stems from a combination of top-line revenue growth, gradual financial deleveraging, and tax efficiency. The net margin reached 10.6% for the quarter, expanding 220 basis points compared to the third quarter of 2025.
Financial leverage remained controlled, closing the period between 1.0x and 1.56x Net Debt/EBITDA. In a high-interest-rate environment in Brazil, containing the cost of debt—contracted at CDI + 0.68%—was crucial to preventing financial expenses from eating into operational results. Additionally, strategic moves in the interior of São Paulo and Minas Gerais, such as the acquisition of Unilab for R$ 55 million, reinforced regional presence without destabilizing the company's cash position.
On the other hand, investors should note that the average ticket per test stood at R$ 37.49 in Q3 2026, remaining practically flat year-over-year. Revenue growth came from total volume in tests and services rendered rather than price increases passed on to health insurers—a direct reflection of tough negotiations in the supplemental healthcare sector.
Does FLRY3 Pay Monthly Dividends? How Often Does the Company Distribute Payouts?
No, FLRY3 does not pay monthly dividends. Grupo Fleury follows a payout policy of distributing earnings 2 to 4 times a year, split between interim dividends and Interest on Equity (JCP).
Over the trailing 12 months, the company distributed R$ 1.30 per share in payouts, representing a dividend yield of approximately 6.39% against the share price of R$ 20.34 recorded in November 2026. Recent milestones in the company's payout dynamics include the announcement of distributions via interest on equity and an accelerated JCP distribution schedule at the end of the third quarter.
| Indicator (Fundamentus/B3) | Updated Figure (Q3 2026) | Market Read |
|---|---|---|
| Price / Earnings (P/E) | 15.7x | In line with recent historical averages |
| EV / EBITDA | 6.5x | Attractive multiple for the healthcare sector |
| Price / Book Value (P/B) | 2.04x | Premium justified by the 18.7% ROIC |
| Dividend Yield (12M) | 6.39% | Recurring payouts via JCP and dividends |
| Fair Value (Site Valuation) | R$ 19.02 | -7.0% margin of safety versus R$ 20.34 |
Is FLRY3 a Buy or Sell After These Earnings?
The answer depends on how shareholders view the risk-return trade-off. From an operational fundamentals standpoint, Q3 2026 proved the scale thesis. Fleury has solidified its position as a relevant defensive asset, in clear contrast to the volatility and risks mapped out for sector competitors like Hapvida and Dasa in the post-election and high-interest-rate environment.
However, from a strict valuation perspective, Fleury shares trade at R$ 20.34, while the fair value calculated by our methodology sits at R$ 19.02 (with a tolerance range between R$ 14.90 and R$ 25.37). This leaves the asset with a slightly negative margin of safety (-7.0%), indicating that the market has already priced in a significant part of the operational recovery.
For investors focused on income and operational quality, the Q3 2026 results offer reassurance: cash generation is strong, an 18.7% ROIC ensures adequate returns on invested capital, and dividends remain secure. For new purchases, the lack of a margin of safety suggests entry caution, prioritizing market pullbacks.
What Should Investors Track in Fleury Over Coming Quarters?
For upcoming quarters, FLRY3 investors should monitor four fundamental vectors to keep the thesis intact:
- Synergies and Efficiency: The ability to keep ROIC above 18% and the EBITDA margin around 27% as further integrations progress.
- Free Cash Generation: Maintaining payout distributions without compromising financial deleveraging (leverage below 1.5x EBITDA).
- Average Ticket Pressure: Monitoring whether growth continues to rely on test volume or if the company can expand average pricing per visit.
- Debt Cost: The behavior of the Selic rate and CDI benchmark on financial expenses for debt issued at CDI + 0.68%.
Verdict: Hold FLRY3 Shares
Fleury's Q3 2026 earnings were excellent from an operational standpoint, showing R$ 264.3 million in net income and a real acceleration in profitability. However, trading at R$ 20.34 against a fair value of R$ 19.02, FLRY3 is fairly priced by the market. The house recommendation is to hold for current shareholders, enjoying regular dividend distributions without rushing to expand positions outside of a comfortable margin of safety.
